Recently, the LAmbre™ Left Atrial Appendage Closure (LAAC) Master Session was successfully held by LifeTech Scientific Corporation. Thirteen well-known cardiovascular experts gathered online to share their clinical experience with the LAmbre™ LAAC system.
LAmbre™ Implantation Data and Clinical Experience Sharing
Professor Zhou Daxin from Fudan University Zhongshan Hospital shared the implantation data and clinical experience of using the LAmbre™ LAAC system in the hospital. Professor Zhou compared the relevant data of the LAmbre™ device with the plug-shaped LAAC devices. It showed that the perioperative leakage rate is only 2.68% when using the LAmbre™ device, while the data of the plug-shaped LAAC devices is 6.05%. Subsequently, through the introduction of two LAmbre™ LAAC cases, Professor Zhou further proved that the LAAC with LAmbre™ device is safe and effective in the prevention of atrial fibrillation（AF）stroke.
Professor Huang Weijian from the First Affiliated Hospital of Wenzhou Medical University shared the clinical experience and implantation data of the LAmbre™ LAAC system in the hospital, and he interpreted the standardized operating process of the LAAC in details. Professor Huang emphasized，the LAmbre™ device is safe and effective, and it was designed with a wide range of specifications, making it could be adapted to a variety of LAA anatomic structures, which allows wider clinical applications. Besides, with the LAmbre™ device, the procedure could achieve a better occluder deployment accuracy and higher procedure success rate, providing patients and doctors with a premium treatment option.
LAAC Postoperative Medication Discussion
Professor Jiang Chenyang from Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, led the discussion of the postoperative medication of the LAAC, and he summarized the common medication in the world: 1. Warfarin; 2. New oral anticoagulant (NOAC); 3. Warfarin + Aspirin; 4. NOAC + Aspirin; 5. Dual antiplatelet. For patients with low bleeding risk, experts recommend Warfarin or NOAC, and for patients with high bleeding risk, the NOAC is suggested. In addition, it is important to reduce the dosage as appropriate for low-weight elderly people with a hemorrhage history.
Lambre™ Device with Partial Distal Deployment Technique
Professor Xiao Fangyi from the First Affiliated Hospital of Wenzhou Medical University shared his LAAC experience of using the LAmbre™ device with “partial distal deployment” technique. Professor Xiao compared the traditional deployment method with the “partial distal deployment” technique, and the data proved the “partial distal deployment” technique can effectively reduce the retrieve of the device during the procedure and decrease the potential device-related injury to the LAA. In addition, Professor Xiao pointed out, although the “partial distal deployment” technique has a distinct advantage, the device deployment method is still needed to be selected based on the patient’s condition.
In the case sharing session, Professor Zhang Xiaochun from Fudan University Zhongshan Hospital shared a LAAC case conducted in the hospital. The patient’s LAA has a well-developed pectinate muscles and was observed to have a strong contraction, which made the case very challenging. For this challenging LAAC case, Professor Zhang adapted the LAmbre™ device and achieved a successful closure.
The LAmbre™ LAAC Master Session was closed with a great success! Experts agreed the LAmbre™ LAAC system is an outstanding LAAC device providing a premium treatment for AF stroke patients, and they believed this novel device would have a very bright future.